Haixi Pharma Reports No Share Capital Changes and Confirms Adequate Public Float for October 2026

Bulletin Express11-02

Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) filed its Monthly Return for Equity Issuer covering the period ended 31 October 2026, showing a stable capital structure with no new share issuances, cancellations, or treasury share activity.

Authorised and Issued Share Capital • Authorised ordinary H-share capital remained at 78.71 million shares with a par value of RMB 1.00 each, equivalent to authorised capital of RMB 78.71 million. • Issued share capital was unchanged at 78.71 million shares; no shares were held in treasury. • Consequently, total issued shares at month-end stood at 78.71 million, identical to the previous month.

Public Float Compliance Haixi Pharma confirmed compliance with the Main Board’s minimum public float threshold of 25 % of issued H shares as of 31 October 2026.

Capital Instruments The company reported no outstanding share options, warrants, convertible securities, depositary receipts or other arrangements that could dilute existing shareholders.

Governance The filing was submitted by Joint Company Secretary Mr. Zhang Junhuan on 2 November 2026, in accordance with Hong Kong Stock Exchange requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment